Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive
deficits are already present at the first break of the illness, seem to remain stable during
early phases and noticeably influence daily functioning. Differences among antipsychotics in
terms of cognitive effectiveness have turned out to be a topic of increasing research
interest. The initially postulated superior neurocognitive effectiveness of second-generation
antipsychotics (SGAs) compared to first-generation antipsychotics (FGAs) is currently under
debate. Long-term studies would be of great value to evaluate the differential benefits
exerted by antipsychotic drugs on cognitive performance. The aim of this study is to
investigate the cognitive effects of aripiprazole, quetiapine and ziprasidone in
first-episode psychosis at 1 year.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborators:
Centro de Investigación Biomédica en Red de Salud Mental Instituto de Investigación Marqués de Valdecilla